Filing Details
- Accession Number:
- 0001104659-19-020514
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-04-09 18:27:04
- Reporting Period:
- 2019-04-08
- Accepted Time:
- 2019-04-09 18:27:04
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1426332 | Ngm Biopharmaceuticals Inc | NGM | Pharmaceutical Preparations (2834) | NJ |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 310158 | Merck & Co., Inc. | 2000 Galloping Hill Road Kenilworth NJ 07033 | No | No | Yes | No | |
| 942443 | Merck Sharp & Dohme Corp. | One Merck Drive Whitehouse Station NJ 08889 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-04-08 | 8,833,333 | $0.00 | 8,833,333 | No | 4 | C | Indirect | See Footnote |
| Common Stock | Acquisiton | 2019-04-08 | 4,121,683 | $16.00 | 12,955,016 | No | 4 | P | Indirect | See Footnote |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | See Footnote |
| No | 4 | P | Indirect | See Footnote |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series E Convertible Preferred Stock | Disposition | 2019-04-08 | 17,666,666 | $0.00 | 8,333,333 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect |
Footnotes
- Each share of Series E Convertible Preferred Stock automatically converted into one-half (0.5) of a share of common stock immediately prior to the closing of the Issuer's initial public offering, and has no expiration date.
- These securities are owned directly by Merck Sharp & Dohme Corp., which is a direct, wholly owned subsidiary of Merck & Co., Inc. ("Merck"). Merck is an indirect beneficial owner of the reported securities.
Billionaire Hedge Funds
